DDInter1042 DDInter1032
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Lefamulin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Lefamulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Lefamulin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lefamulin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Octreotide
Lefamulin may lead to a major life threatening interaction when taken with Vandetanib
Lefamulin may lead to a major life threatening interaction when taken with Macimorelin